title: [Rituximab for treatment of Felty’s syndrome].
abstract: Felty’s syndrome is a rare variant of severe seropositive rheumatoid arthritis with neutropenia and splenomegaly. It is difficult to treat and associated with a poor prognosis due to the substantial risk of infections. This article presents the case of a patient with refractory disease who responded to rituximab with permanent normalization of neutrophil counts. Repeated infusions were necessary to induce and maintain remission.
authors.forename: H
authors.initials: H
authors.lastname: Becker
authors.forename: H
authors.initials: H
authors.lastname: Appel
authors.forename: T
authors.initials: T
authors.lastname: Fassbinder
authors.forename: D
authors.initials: D
authors.lastname: Heitzmann
authors.forename: P
authors.initials: P
authors.lastname: Willeke
authors.forename: A M
authors.initials: AM
authors.lastname: Jacobi
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage; D005258:Felty Syndrome / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D008297:Male; D009503:Neutropenia / Q000175:diagnosis* / Q000188:drug therapy*; D000069283:Rituximab; D013163:Splenomegaly / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D000069283:Rituximab